Search clinical trials for: bimatoprost Formulation A

Total 11852 results

GlaxoSmithKline

Completed

Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)/5 Milliliter (mL) Suspension Versus Cefixime 200 mg/5 mL Suspension Reference Product in Healthy Adult Subjects Under Fasting Conditions

Infections, Bacterial

South Africa
AbbVie

Active, not recruiting

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States, Argentina, Australia, Bulgaria, Czechia, Denmark, Germany, Hungary, Ireland, Italy, New Zealand, Poland, Russian Federation, South Africa, Sweden, United Kingdom
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis

Eyelash Hypotrichosis

Japan
Alcon Research

Completed

Evaluation of Safety and Tolerability of Ocular Lubricants

Dry Eye

Australia
Allergan

Completed

Bimatoprost for the Treatment of Eyebrow Hypotrichosis

Eyebrow Hypotrichosis

United States, Canada
GlaxoSmithKline

Completed

A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects

Crohn's Disease

United States
AbbVie

Completed

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
Allergan

Completed

A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension

Glaucoma | Open-Angle Ocular Hypertension

Spain, United States, Singapore, Australia, Denmark, France, Poland, Russian Federation, Thailand
Allergan

Completed

A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Laboratoires Thea

Completed

Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers

Healthy Volunteers

United States
Johns Hopkins University

Recruiting

Bimatoprost as a Treatment for Graves' Orbitopathy

Graves Ophthalmopathy

United States
Allergan

Completed

Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Ocular Hypertension | Glaucoma, Open-Angle

Netherlands
Allergan

Completed

A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Ocular Hypertension | Glaucoma, Open-Angle

Germany
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension

United States
Allergan

Completed

Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence

Eyelash Hypotrichosis

United States
Inventprise Inc.
PATH; Canadian Center for Vaccinology; Vaccine Evaluation Center, Canada

Active, not recruiting

Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

Pneumococcal Vaccines

Canada
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis

Eyelash Hypotrichosis

Japan
AbbVie

Completed

Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

United States, Australia, Canada, Denmark, France, Germany, Israel, New Zealand, Philippines, Poland, Russian Federation, United Kingdom
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)

Ocular Hypertension | Glaucoma, Open-Angle

Korea, Republic of
University of Miami

Completed

Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes

Hypertrichosis

United States
TaiGen Biotechnology Co., Ltd.

Completed

Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy Volunteers

Healthy

United States
Allergan

Completed

A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension (LOTUS)

Ocular Hypertension | Glaucoma, Open-Angle

China
Allergan

Completed

An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes

Eyelash Hypotrichosis

United States
Allergan

Completed

A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension (LOTUSDI)

Ocular Hypertension | Glaucoma, Open-Angle

China
Allergan

Completed

Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye

Dry Eye Syndromes

United States
SCF Pharma
Institut de recherche clinique du littoral (IRCL)

Recruiting

Omega-3 Monoglyceride Based Topic Products as Skin Prebiotics for Eczema

Eczema

Canada
Allergan

Completed

Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects

Eyelash Hypotrichosis

Korea, Republic of
ForSight Vision5, Inc.

Completed

Bimatoprost Ocular Insert Pharmacokinetic Study

Healthy Volunteers

United States
Indiana University School of Medicine

Completed

Bioavailability of Bimatoprost Ophthalmic Solution in Human Aqueous.

Cataract

United States
GlycosBio, Inc.
Center for Clinical Studies, Texas

Recruiting

Assessment of the Effects on the Skin Microbiome of Amending an Over-the-counter Eczema Product With Activated Oil (AO)

Eczema

United States
Allergan

Completed

A Study of Bimatoprost 0.01% in the Clinical Setting (APPEAL-Taiwan)

Ocular Hypertension | Glaucoma, Primary Open Angle

Taiwan
Allergan

Completed

A Study of LUMIGAN® RC in the Clinical Setting

Ocular Hypertension | Glaucoma, Primary Open Angle

Canada
Boehringer Ingelheim

Completed

Bioavailability of Four Oral Prototype Extended Release Formulations With BI 11634 in Healthy Male Volunteers

Healthy
Rabin Medical Center

Completed

Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues

Thyroid Associated Ophthalmopathies

Israel
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada

Tetanus Immunisation (Healthy Volunteers) | Diphtheria Immunisation (Healthy Volunteers) | Pertussis Immunisation (Healthy Volunteers)

Canada
Laboratoires Thea

Completed

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Ocular Hypertension | Glaucoma

United States, Colombia
Allergan

Completed

Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

Hypotrichosis

United States
Salus University

Not yet recruiting

Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma (NTG)

Normal Tension Glaucoma

United States
AbbVie

Enrolling by invitation

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR (Maia)

Ocular Hypertension | Open-Angle Glaucoma

United States, Argentina, Belgium, Brazil, Canada, Colombia, Czechia, Denmark, Egypt, France, Germany, Hong Kong, Italy, Korea, Republic of, New Zealand, Peru, Philippines, Poland, Russian Federation, Singapore, South Africa, Spain, Thailan... and more
University of California, San Diego

Completed

24-hour IOP-lowering Effect of 0.01% Bimatoprost

Ocular Hypertension | Glaucoma | Intraocular Pressure

United States
Innovative Medical

Completed

Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%

Glaucoma

United States
Amneal Pharmaceuticals, LLC
CBCC Global Inc.; Amneal EU, Limited

Not yet recruiting

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Ocular Hypertension | Open-angle Glaucoma

United States
Duke University

Completed

Study of Bimatoprost Gel on Eyelash Growth

Hypotrichosis | Madarosis

United States
AbbVie

Available

Expanded Access to Bimatoprost (Durysta)

Open-angle Glaucoma
Orion Corporation, Orion Pharma
Endo Pharmaceuticals

Completed

Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer (ARAFOR)

Prostate Cancer

Latvia
Laboratoires Thea

Completed

Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose

Primary Open Angle Glaucoma | Ocular Hypertension

France
Pfizer
Arvinas Estrogen Receptor, Inc.

Recruiting

A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults

Healthy

United States
AstraZeneca

Completed

To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers

Parkinson's Disease

United Kingdom
Amneal Pharmaceuticals, LLC
CBCC Global Research

Recruiting

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

Ocular Hypertension | Glaucoma, Open-Angle

United States

3

Subscribe